Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Клиническое значение ПЭТ/КТ в диагностике первичных злокачественных опухолей надпочечников
Клиническое значение ПЭТ/КТ в диагностике первичных злокачественных опухолей надпочечников
Огнерубов Н.А., Антипова Т.С., Мирсалимова О.О., Поддубная И.В. Клиническое значение ПЭТ/КТ в диагностике первичных злокачественных опухолей надпочечников. Современная Онкология. 2024;26(3):374–379. DOI: 10.26442/18151434.2024.3.202923
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
DOI: 10.26442/18151434.2024.3.202923
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
________________________________________________
DOI: 10.26442/18151434.2024.3.202923
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Введение. Согласно литературным сведениям роль комбинированной позитронно-эмиссионной и рентгеновской компьютерной томографии (ПЭТ/КТ) в диагностике первичных опухолей надпочечников (ОН) остается ограниченной, что обусловлено как частотой данных новообразований, так и возможностью использования метода. Такая ситуация требует проведения различных изысканий по оценке диагностических ресурсов ПЭТ/КТ с 18-фтордезоксиглюкозой (18F-ФДГ).
Цель. Оценить клиническую роль ПЭТ/КТ с 18F-ФДГ в диагностике первичных злокачественных ОН (ЗОН).
Материалы и методы. В исследование включены 9 пациентов, из них 5 мужчин и 4 женщины в возрасте 44–76 лет, медиана – 59,3 года, с морфологически подтвержденным диагнозом ЗОН. Всем больным выполнена ПЭТ/КТ с 18F-ФДГ.
Результаты. Проводили визуальный и количественный анализ полученных изображений, включая определение стандартизированного коэффициента максимального накопления (SUVmax) в опухоли, печени и селезенке, отношения SUVmax первичной опухоли к SUVmax в печени и селезенке. Опухоли чаще локализовались справа – 5/55,6%, в одном случае – с 2 сторон. Максимальный размер образования надпочечников в среднем составил 6,8 см, а минимальный – 6,0 см. Медиана SUVmax в ОН составила 10,0 (3,54–22,29), в то время как в печени и селезенке – 3,16 и 2,34 соответственно, а соотношение SUVmax в опухоли к SUVmax в печени и селезенке – 3,33 и 4,48.
Заключение. Среди методов медицинской визуализации гибридная технология ПЭТ/КТ с 18F-ФДГ обеспечивает высокую диагностическую точность первичных ЗОН. ПЭТ/КТ показала значительное поглощение опухолью 18F-ФДГ, при этом медиана SUVmax составила 10,0, а соотношение SUVmax в опухоли к SUVmax в печени и селезенке – 3,33 и 4,48 соответственно. ПЭТ/КТ с 18F-ФДГ может являться методом выбора диагностики первичных ОН.
Ключевые слова: первичные опухоли надпочечников, злокачественные, диагностика, ПЭТ/КТ с 18-фтордезоксиглюкозой, SUVmax
Aim. To evaluate the clinical role of PET/CT with 18F-FDG in the diagnosis of primary adrenal malignancies (PAM).
Materials and methods. The study included 9 patients, 5 males and 4 females aged 44–76, with a median age of 59.3 years, with a morphologically confirmed diagnosis of the PAM. All patients underwent PET/CT with 18F-FDG. Visual and quantitative analysis of the obtained images was performed, including determination of the standardized maximum accumulation coefficient (SUVmax) in the tumor, liver, and spleen, the ratio of SUVmax of the primary tumor to SUVmax in the liver and spleen. Tumors were more often localized on the right (5/55.6%), and one case was bilateral. The maximum size of the adrenal mass averaged 6.8 cm (3.2–11.2) and the minimum size was 6.0 cm (2.3–9.0). The median SUVmax in AT was 10.0 (3.54–22.29), while in liver and spleen, it was 3.16 and 2.34, respectively, and the ratio of tumor SUVmax to liver and spleen SUVmax was 3.33 and 4.48, respectively.
Conclusion. Hybrid PET/CT with 18F-FDG is a medical imaging method with a high diagnostic accuracy of PAM. PET/CT showed significant 18F-FDG tumor uptake, with a median SUVmax of 10.0 and a ratio of tumor SUVmax to liver and spleen SUVmax of 3.33 and 4.48, respectively. PET/CT with 18F-FDG may be a method of choice for diagnosing primary ATs.
Keywords: primary adrenal tumors, malignant, diagnosis, PET/CT with 18-fluorodeoxyglucose, SUVmax
Цель. Оценить клиническую роль ПЭТ/КТ с 18F-ФДГ в диагностике первичных злокачественных ОН (ЗОН).
Материалы и методы. В исследование включены 9 пациентов, из них 5 мужчин и 4 женщины в возрасте 44–76 лет, медиана – 59,3 года, с морфологически подтвержденным диагнозом ЗОН. Всем больным выполнена ПЭТ/КТ с 18F-ФДГ.
Результаты. Проводили визуальный и количественный анализ полученных изображений, включая определение стандартизированного коэффициента максимального накопления (SUVmax) в опухоли, печени и селезенке, отношения SUVmax первичной опухоли к SUVmax в печени и селезенке. Опухоли чаще локализовались справа – 5/55,6%, в одном случае – с 2 сторон. Максимальный размер образования надпочечников в среднем составил 6,8 см, а минимальный – 6,0 см. Медиана SUVmax в ОН составила 10,0 (3,54–22,29), в то время как в печени и селезенке – 3,16 и 2,34 соответственно, а соотношение SUVmax в опухоли к SUVmax в печени и селезенке – 3,33 и 4,48.
Заключение. Среди методов медицинской визуализации гибридная технология ПЭТ/КТ с 18F-ФДГ обеспечивает высокую диагностическую точность первичных ЗОН. ПЭТ/КТ показала значительное поглощение опухолью 18F-ФДГ, при этом медиана SUVmax составила 10,0, а соотношение SUVmax в опухоли к SUVmax в печени и селезенке – 3,33 и 4,48 соответственно. ПЭТ/КТ с 18F-ФДГ может являться методом выбора диагностики первичных ОН.
Ключевые слова: первичные опухоли надпочечников, злокачественные, диагностика, ПЭТ/КТ с 18-фтордезоксиглюкозой, SUVmax
________________________________________________
Aim. To evaluate the clinical role of PET/CT with 18F-FDG in the diagnosis of primary adrenal malignancies (PAM).
Materials and methods. The study included 9 patients, 5 males and 4 females aged 44–76, with a median age of 59.3 years, with a morphologically confirmed diagnosis of the PAM. All patients underwent PET/CT with 18F-FDG. Visual and quantitative analysis of the obtained images was performed, including determination of the standardized maximum accumulation coefficient (SUVmax) in the tumor, liver, and spleen, the ratio of SUVmax of the primary tumor to SUVmax in the liver and spleen. Tumors were more often localized on the right (5/55.6%), and one case was bilateral. The maximum size of the adrenal mass averaged 6.8 cm (3.2–11.2) and the minimum size was 6.0 cm (2.3–9.0). The median SUVmax in AT was 10.0 (3.54–22.29), while in liver and spleen, it was 3.16 and 2.34, respectively, and the ratio of tumor SUVmax to liver and spleen SUVmax was 3.33 and 4.48, respectively.
Conclusion. Hybrid PET/CT with 18F-FDG is a medical imaging method with a high diagnostic accuracy of PAM. PET/CT showed significant 18F-FDG tumor uptake, with a median SUVmax of 10.0 and a ratio of tumor SUVmax to liver and spleen SUVmax of 3.33 and 4.48, respectively. PET/CT with 18F-FDG may be a method of choice for diagnosing primary ATs.
Keywords: primary adrenal tumors, malignant, diagnosis, PET/CT with 18-fluorodeoxyglucose, SUVmax
Полный текст
Список литературы
1. Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476-90. DOI:10.1016/j.annonc.2020.08.2099
2. Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg.
2006;30(5):872-8. DOI:10.1007/s00268-005-0329-x
3. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579-86. DOI:10.1016/j.ejca.2013.02.034
4. McLean K, Lilienfeld H, Caracciolo JT, et al. Management of isolated Adrenal Lesions in Cancer Patients. Cancer Control. 2011;18(2):113-26. DOI:10.1177/107327481101800206
5. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190(5):1163-8. DOI:10.2214/AJR.07.2799
6. Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas: current status. AJR Am J Roentgenol. 2002;179(3):559-68. DOI:10.2214/ajr.179.3.1790559
7. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology. 2011;259(1):117-26. DOI:10.1148/radiol.11100569
8. Kandathil A, Wong KK, Wale DJ, et al. Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature. Endocrine. 2015;49(1):6-26. DOI:10.1007/s12020-014-0440-6
9. Корб Т.А., Чернина В.Ю., Блохин И.А., и др. Визуализация надпочечников: в норме и при патологии (обзор литературы). Проблемы Эндокринологии. 2021;67(3):26-36 [Korb TA, Chernina VYu, Blokhin IA, et al. Adrenal imaging: anatomy and pathology (literature review). Problems of Endocrinology. 2021;67(3):26-36 (in Russian)]. DOI:10.14341/probl12752
10. Koç ZP, Özcan PP, Sezer E, et al. The F-18 FDG PET/CT evaluation of the metastatic adrenal lesions of the non-lung cancer tumors compared with pathology results. Egypt J Radiol Nucl Med. 2022;53. DOI:10.1186/s43055-021-00663-2
11. Saito H, Shuto K, Ota T, et al. A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma. Gan To Kagaku Ryoho. 2010;37(12):2406-8 (in Japanese).
12. Drouet C, Morel O, Boulahdour H. Bilateral Huge Incidentalomas of Isolated Adrenal Metastases From Unknown Primary Melanoma Revealed by 18F-FDG PET/CT. Clin Nucl Med. 2017;42(1):e51-3. DOI:10.1097/RLU.0000000000001417
13. Furukawa K, Yoshitoshi K, Eguchi R. A long survival case of metastatic left adrenal gland tumor from undifferentiated carcinoma of thoracic esophagus. J Jpn Coll Surg.
2012;37:248-51.
14. Kim SJ, Lee SW, Pak K, et al. Diagnostic accuracy of (18)F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol. 2018;91(1086):20170520. DOI:10.1259/bjr.20170520
15. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1-G42. DOI:10.1093/ejendo/lvad066
16. Cistaro A, Niccoli Asabella A, Coppolino P, et al. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies – a multicenter experience. Hell J Nucl Med. 2015;18(2):97-102. DOI:10.1967/s002449910202
17. Wong KK, Miller BS, Viglianti BL, et al. Molecular Imaging in the Management of Adrenocortical Cancer: A Systematic Review. Clin Nucl Med. 2016;41(8):e368-82. DOI:10.1097/RLU.0000000000001112
18. Schlötelburg W, Hartrampf PE, Kosmala A, et al. Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma. Endocrine.
2024;84(3):1172-81. DOI:10.1007/s12020-024-03695-6
19. Kim JY, Kim SH, Lee HJ, et al. Utilisation of combined 18F-FDG PET/CT scan for differential diagnosis between benign and malignant adrenal enlargement. Br J Radiol. 2013;86(1028):20130190. DOI:10.1259/bjr.20130190
20. Arikan AE, Makay O, Teksoz S, et al. Efficacy of PET-CT in the prediction of metastatic adrenal masses that are detected on follow-up of the patients with prior nonadrenal malignancy: A nationwide multicenter case-control study. Medicine (Baltimore). 2022;101(34):e30214. DO:10.1097/MD.0000000000030214
21. Ma G, Zhang X, Wang M, et al. Role of (18)F-FDG PET/CT in the differential diagnosis of primary benign and malignant unilateral adrenal tumors. Quant Imaging Med Surg. 2021;11(5):2013-8. DOI:10.21037/qims-20-875
22. Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47(1):32-7.
23. Okada M, Shimono T, Komeya Y, et al. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med. 2009;23(4):349-54. DOI:10.1007/s12149-009-0246-4
24. Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy – initial experience. Radiology. 2006;238(3):970-7. DOI:10.1148/radiol.2383042164
25. Boland GW, Blake MA, Holalkere NS, Hahn PF. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am J Roentgenol. 2009;192(4):956-62. DOI:10.2214/AJR.08.1431
26. Vos EL, Grewal RK, Russo AE, et al. Predicting malignancy in patients with adrenal tumors using (18) F-FDG-PET/CT SUVmax. J Surg Oncol.
2020;122(8):1821-6. DOI:10.1002/jso.26203
27. Perri M, Erba P, Volterrani D, et al. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. AJR Am J Roentgenol. 2011;197(1):209-16. DOI:10.2214/AJR.10.5342
28. Launay N, Silvera S, Tenenbaum F, et al. Value of 18-F-FDG PET/CT and CT in the Diagnosis of Indeterminate Adrenal Masses. Int J Endocrinol. 2015;2015:213875. DOI:10.1155/2015/213875
29. Watanabe H, Kanematsu M, Goshima S, et al. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT. Ann Nucl Med. 2013;27(7):648-53. DOI:10.1007/s12149-013-0730-8
2. Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg.
2006;30(5):872-8. DOI:10.1007/s00268-005-0329-x
3. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579-86. DOI:10.1016/j.ejca.2013.02.034
4. McLean K, Lilienfeld H, Caracciolo JT, et al. Management of isolated Adrenal Lesions in Cancer Patients. Cancer Control. 2011;18(2):113-26. DOI:10.1177/107327481101800206
5. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190(5):1163-8. DOI:10.2214/AJR.07.2799
6. Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas: current status. AJR Am J Roentgenol. 2002;179(3):559-68. DOI:10.2214/ajr.179.3.1790559
7. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology. 2011;259(1):117-26. DOI:10.1148/radiol.11100569
8. Kandathil A, Wong KK, Wale DJ, et al. Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature. Endocrine. 2015;49(1):6-26. DOI:10.1007/s12020-014-0440-6
9. Korb TA, Chernina VYu, Blokhin IA, et al. Adrenal imaging: anatomy and pathology (literature review). Problems of Endocrinology. 2021;67(3):26-36 (in Russian). DOI:10.14341/probl12752
10. Koç ZP, Özcan PP, Sezer E, et al. The F-18 FDG PET/CT evaluation of the metastatic adrenal lesions of the non-lung cancer tumors compared with pathology results. Egypt J Radiol Nucl Med. 2022;53. DOI:10.1186/s43055-021-00663-2
11. Saito H, Shuto K, Ota T, et al. A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma. Gan To Kagaku Ryoho. 2010;37(12):2406-8 (in Japanese).
12. Drouet C, Morel O, Boulahdour H. Bilateral Huge Incidentalomas of Isolated Adrenal Metastases From Unknown Primary Melanoma Revealed by 18F-FDG PET/CT. Clin Nucl Med. 2017;42(1):e51-3. DOI:10.1097/RLU.0000000000001417
13. Furukawa K, Yoshitoshi K, Eguchi R. A long survival case of metastatic left adrenal gland tumor from undifferentiated carcinoma of thoracic esophagus. J Jpn Coll Surg.
2012;37:248-51.
14. Kim SJ, Lee SW, Pak K, et al. Diagnostic accuracy of (18)F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol. 2018;91(1086):20170520. DOI:10.1259/bjr.20170520
15. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1-G42. DOI:10.1093/ejendo/lvad066
16. Cistaro A, Niccoli Asabella A, Coppolino P, et al. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies – a multicenter experience. Hell J Nucl Med. 2015;18(2):97-102. DOI:10.1967/s002449910202
17. Wong KK, Miller BS, Viglianti BL, et al. Molecular Imaging in the Management of Adrenocortical Cancer: A Systematic Review. Clin Nucl Med. 2016;41(8):e368-82. DOI:10.1097/RLU.0000000000001112
18. Schlötelburg W, Hartrampf PE, Kosmala A, et al. Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma. Endocrine.
2024;84(3):1172-81. DOI:10.1007/s12020-024-03695-6
19. Kim JY, Kim SH, Lee HJ, et al. Utilisation of combined 18F-FDG PET/CT scan for differential diagnosis between benign and malignant adrenal enlargement. Br J Radiol. 2013;86(1028):20130190. DOI:10.1259/bjr.20130190
20. Arikan AE, Makay O, Teksoz S, et al. Efficacy of PET-CT in the prediction of metastatic adrenal masses that are detected on follow-up of the patients with prior nonadrenal malignancy: A nationwide multicenter case-control study. Medicine (Baltimore). 2022;101(34):e30214. DO:10.1097/MD.0000000000030214
21. Ma G, Zhang X, Wang M, et al. Role of (18)F-FDG PET/CT in the differential diagnosis of primary benign and malignant unilateral adrenal tumors. Quant Imaging Med Surg. 2021;11(5):2013-8. DOI:10.21037/qims-20-875
22. Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47(1):32-7.
23. Okada M, Shimono T, Komeya Y, et al. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med. 2009;23(4):349-54. DOI:10.1007/s12149-009-0246-4
24. Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy – initial experience. Radiology. 2006;238(3):970-7. DOI:10.1148/radiol.2383042164
25. Boland GW, Blake MA, Holalkere NS, Hahn PF. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am J Roentgenol. 2009;192(4):956-62. DOI:10.2214/AJR.08.1431
26. Vos EL, Grewal RK, Russo AE, et al. Predicting malignancy in patients with adrenal tumors using (18) F-FDG-PET/CT SUVmax. J Surg Oncol.
2020;122(8):1821-6. DOI:10.1002/jso.26203
27. Perri M, Erba P, Volterrani D, et al. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. AJR Am J Roentgenol. 2011;197(1):209-16. DOI:10.2214/AJR.10.5342
28. Launay N, Silvera S, Tenenbaum F, et al. Value of 18-F-FDG PET/CT and CT in the Diagnosis of Indeterminate Adrenal Masses. Int J Endocrinol. 2015;2015:213875. DOI:10.1155/2015/213875
29. Watanabe H, Kanematsu M, Goshima S, et al. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT. Ann Nucl Med. 2013;27(7):648-53. DOI:10.1007/s12149-013-0730-8
2. Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg.
2006;30(5):872-8. DOI:10.1007/s00268-005-0329-x
3. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579-86. DOI:10.1016/j.ejca.2013.02.034
4. McLean K, Lilienfeld H, Caracciolo JT, et al. Management of isolated Adrenal Lesions in Cancer Patients. Cancer Control. 2011;18(2):113-26. DOI:10.1177/107327481101800206
5. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190(5):1163-8. DOI:10.2214/AJR.07.2799
6. Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas: current status. AJR Am J Roentgenol. 2002;179(3):559-68. DOI:10.2214/ajr.179.3.1790559
7. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology. 2011;259(1):117-26. DOI:10.1148/radiol.11100569
8. Kandathil A, Wong KK, Wale DJ, et al. Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature. Endocrine. 2015;49(1):6-26. DOI:10.1007/s12020-014-0440-6
9. Корб Т.А., Чернина В.Ю., Блохин И.А., и др. Визуализация надпочечников: в норме и при патологии (обзор литературы). Проблемы Эндокринологии. 2021;67(3):26-36 [Korb TA, Chernina VYu, Blokhin IA, et al. Adrenal imaging: anatomy and pathology (literature review). Problems of Endocrinology. 2021;67(3):26-36 (in Russian)]. DOI:10.14341/probl12752
10. Koç ZP, Özcan PP, Sezer E, et al. The F-18 FDG PET/CT evaluation of the metastatic adrenal lesions of the non-lung cancer tumors compared with pathology results. Egypt J Radiol Nucl Med. 2022;53. DOI:10.1186/s43055-021-00663-2
11. Saito H, Shuto K, Ota T, et al. A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma. Gan To Kagaku Ryoho. 2010;37(12):2406-8 (in Japanese).
12. Drouet C, Morel O, Boulahdour H. Bilateral Huge Incidentalomas of Isolated Adrenal Metastases From Unknown Primary Melanoma Revealed by 18F-FDG PET/CT. Clin Nucl Med. 2017;42(1):e51-3. DOI:10.1097/RLU.0000000000001417
13. Furukawa K, Yoshitoshi K, Eguchi R. A long survival case of metastatic left adrenal gland tumor from undifferentiated carcinoma of thoracic esophagus. J Jpn Coll Surg.
2012;37:248-51.
14. Kim SJ, Lee SW, Pak K, et al. Diagnostic accuracy of (18)F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol. 2018;91(1086):20170520. DOI:10.1259/bjr.20170520
15. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1-G42. DOI:10.1093/ejendo/lvad066
16. Cistaro A, Niccoli Asabella A, Coppolino P, et al. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies – a multicenter experience. Hell J Nucl Med. 2015;18(2):97-102. DOI:10.1967/s002449910202
17. Wong KK, Miller BS, Viglianti BL, et al. Molecular Imaging in the Management of Adrenocortical Cancer: A Systematic Review. Clin Nucl Med. 2016;41(8):e368-82. DOI:10.1097/RLU.0000000000001112
18. Schlötelburg W, Hartrampf PE, Kosmala A, et al. Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma. Endocrine.
2024;84(3):1172-81. DOI:10.1007/s12020-024-03695-6
19. Kim JY, Kim SH, Lee HJ, et al. Utilisation of combined 18F-FDG PET/CT scan for differential diagnosis between benign and malignant adrenal enlargement. Br J Radiol. 2013;86(1028):20130190. DOI:10.1259/bjr.20130190
20. Arikan AE, Makay O, Teksoz S, et al. Efficacy of PET-CT in the prediction of metastatic adrenal masses that are detected on follow-up of the patients with prior nonadrenal malignancy: A nationwide multicenter case-control study. Medicine (Baltimore). 2022;101(34):e30214. DO:10.1097/MD.0000000000030214
21. Ma G, Zhang X, Wang M, et al. Role of (18)F-FDG PET/CT in the differential diagnosis of primary benign and malignant unilateral adrenal tumors. Quant Imaging Med Surg. 2021;11(5):2013-8. DOI:10.21037/qims-20-875
22. Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47(1):32-7.
23. Okada M, Shimono T, Komeya Y, et al. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med. 2009;23(4):349-54. DOI:10.1007/s12149-009-0246-4
24. Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy – initial experience. Radiology. 2006;238(3):970-7. DOI:10.1148/radiol.2383042164
25. Boland GW, Blake MA, Holalkere NS, Hahn PF. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am J Roentgenol. 2009;192(4):956-62. DOI:10.2214/AJR.08.1431
26. Vos EL, Grewal RK, Russo AE, et al. Predicting malignancy in patients with adrenal tumors using (18) F-FDG-PET/CT SUVmax. J Surg Oncol.
2020;122(8):1821-6. DOI:10.1002/jso.26203
27. Perri M, Erba P, Volterrani D, et al. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. AJR Am J Roentgenol. 2011;197(1):209-16. DOI:10.2214/AJR.10.5342
28. Launay N, Silvera S, Tenenbaum F, et al. Value of 18-F-FDG PET/CT and CT in the Diagnosis of Indeterminate Adrenal Masses. Int J Endocrinol. 2015;2015:213875. DOI:10.1155/2015/213875
29. Watanabe H, Kanematsu M, Goshima S, et al. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT. Ann Nucl Med. 2013;27(7):648-53. DOI:10.1007/s12149-013-0730-8
________________________________________________
2. Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg.
2006;30(5):872-8. DOI:10.1007/s00268-005-0329-x
3. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579-86. DOI:10.1016/j.ejca.2013.02.034
4. McLean K, Lilienfeld H, Caracciolo JT, et al. Management of isolated Adrenal Lesions in Cancer Patients. Cancer Control. 2011;18(2):113-26. DOI:10.1177/107327481101800206
5. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190(5):1163-8. DOI:10.2214/AJR.07.2799
6. Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas: current status. AJR Am J Roentgenol. 2002;179(3):559-68. DOI:10.2214/ajr.179.3.1790559
7. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology. 2011;259(1):117-26. DOI:10.1148/radiol.11100569
8. Kandathil A, Wong KK, Wale DJ, et al. Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature. Endocrine. 2015;49(1):6-26. DOI:10.1007/s12020-014-0440-6
9. Korb TA, Chernina VYu, Blokhin IA, et al. Adrenal imaging: anatomy and pathology (literature review). Problems of Endocrinology. 2021;67(3):26-36 (in Russian). DOI:10.14341/probl12752
10. Koç ZP, Özcan PP, Sezer E, et al. The F-18 FDG PET/CT evaluation of the metastatic adrenal lesions of the non-lung cancer tumors compared with pathology results. Egypt J Radiol Nucl Med. 2022;53. DOI:10.1186/s43055-021-00663-2
11. Saito H, Shuto K, Ota T, et al. A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma. Gan To Kagaku Ryoho. 2010;37(12):2406-8 (in Japanese).
12. Drouet C, Morel O, Boulahdour H. Bilateral Huge Incidentalomas of Isolated Adrenal Metastases From Unknown Primary Melanoma Revealed by 18F-FDG PET/CT. Clin Nucl Med. 2017;42(1):e51-3. DOI:10.1097/RLU.0000000000001417
13. Furukawa K, Yoshitoshi K, Eguchi R. A long survival case of metastatic left adrenal gland tumor from undifferentiated carcinoma of thoracic esophagus. J Jpn Coll Surg.
2012;37:248-51.
14. Kim SJ, Lee SW, Pak K, et al. Diagnostic accuracy of (18)F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol. 2018;91(1086):20170520. DOI:10.1259/bjr.20170520
15. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1-G42. DOI:10.1093/ejendo/lvad066
16. Cistaro A, Niccoli Asabella A, Coppolino P, et al. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies – a multicenter experience. Hell J Nucl Med. 2015;18(2):97-102. DOI:10.1967/s002449910202
17. Wong KK, Miller BS, Viglianti BL, et al. Molecular Imaging in the Management of Adrenocortical Cancer: A Systematic Review. Clin Nucl Med. 2016;41(8):e368-82. DOI:10.1097/RLU.0000000000001112
18. Schlötelburg W, Hartrampf PE, Kosmala A, et al. Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma. Endocrine.
2024;84(3):1172-81. DOI:10.1007/s12020-024-03695-6
19. Kim JY, Kim SH, Lee HJ, et al. Utilisation of combined 18F-FDG PET/CT scan for differential diagnosis between benign and malignant adrenal enlargement. Br J Radiol. 2013;86(1028):20130190. DOI:10.1259/bjr.20130190
20. Arikan AE, Makay O, Teksoz S, et al. Efficacy of PET-CT in the prediction of metastatic adrenal masses that are detected on follow-up of the patients with prior nonadrenal malignancy: A nationwide multicenter case-control study. Medicine (Baltimore). 2022;101(34):e30214. DO:10.1097/MD.0000000000030214
21. Ma G, Zhang X, Wang M, et al. Role of (18)F-FDG PET/CT in the differential diagnosis of primary benign and malignant unilateral adrenal tumors. Quant Imaging Med Surg. 2021;11(5):2013-8. DOI:10.21037/qims-20-875
22. Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47(1):32-7.
23. Okada M, Shimono T, Komeya Y, et al. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med. 2009;23(4):349-54. DOI:10.1007/s12149-009-0246-4
24. Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy – initial experience. Radiology. 2006;238(3):970-7. DOI:10.1148/radiol.2383042164
25. Boland GW, Blake MA, Holalkere NS, Hahn PF. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am J Roentgenol. 2009;192(4):956-62. DOI:10.2214/AJR.08.1431
26. Vos EL, Grewal RK, Russo AE, et al. Predicting malignancy in patients with adrenal tumors using (18) F-FDG-PET/CT SUVmax. J Surg Oncol.
2020;122(8):1821-6. DOI:10.1002/jso.26203
27. Perri M, Erba P, Volterrani D, et al. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. AJR Am J Roentgenol. 2011;197(1):209-16. DOI:10.2214/AJR.10.5342
28. Launay N, Silvera S, Tenenbaum F, et al. Value of 18-F-FDG PET/CT and CT in the Diagnosis of Indeterminate Adrenal Masses. Int J Endocrinol. 2015;2015:213875. DOI:10.1155/2015/213875
29. Watanabe H, Kanematsu M, Goshima S, et al. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT. Ann Nucl Med. 2013;27(7):648-53. DOI:10.1007/s12149-013-0730-8
Авторы
Н.А. Огнерубов*1, Т.С. Антипова2, О.О. Мирсалимова2, И.В. Поддубная1
1ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
2АО «К+31», Москва, Россия
*ognerubov_n.a@mail.ru
1Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
2K+31 JSC, Moscow, Russia
*ognerubov_n.a@mail.ru
1ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
2АО «К+31», Москва, Россия
*ognerubov_n.a@mail.ru
________________________________________________
1Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
2K+31 JSC, Moscow, Russia
*ognerubov_n.a@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.